癌症免疫疗法 （ Cancer immunotherapy） 已经彻底改变了癌症的治疗方式，然而许多患者却未能对其产 生响应。激活先天免疫 （ innate immunity ） 为提高治疗效果提供了一种很有前景的方法，但直接调控这 一过程以增强抗肿瘤反应的信号激酶，仍不为人所知。 2026 年 1 月 8 日，武汉大学 张金方 教授团队联合北京大学/深圳湾实验室 雷晓光 教授团队，在 Nature Cancer 期刊发表了题为： CDK10 suppresses nucleic acid sensors-mediated antitumor immunity 的 研究论文。 该研究通过体内 CRISPR 筛选，发现 CDK10 是癌细胞固有的免疫逃逸驱动因子，通过限制 免疫刺激性核 酸的产生抑制抗肿瘤免疫，从而为癌症免疫治疗提供了一个潜在新靶点。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 在这项最新研究中，研究团队进行了体内激酶组 CRISPR 筛选，从中确定了 CDK10 是肿瘤免疫监视的关 键抑制因子。 从机制上来说，CDK10 通过磷酸化 DNMT1 和 RAP80 来减少双链 RNA 和 R-loop ...

Core Viewpoint - Cancer immunotherapy is emerging as a key treatment method for cancer, following surgery, radiotherapy, and chemotherapy, and is expected to see significant market growth in the coming years [1][6][7]. Group 1: Industry Definition and Classification - Cancer immunotherapy aims to activate or enhance the immune system to target tumor cells, utilizing methods such as cytokine therapy, cancer vaccines, T-cell therapy, and immune checkpoint inhibitors [2][4]. Group 2: Current Development Status - Cancer remains a leading health threat, with over 10 million deaths annually. The global anti-cancer drug market is projected to grow from $150.3 billion in 2020 to $253.3 billion in 2024, with cancer immunotherapy expected to reach $69.91 billion, accounting for 27.60% of the market [4][6][7]. Group 3: Industry Chain - The cancer immunotherapy industry chain includes upstream activities such as basic research and drug design, midstream development and production, and downstream medical institutions and testing agencies [8]. Group 4: Development Environment and Policies - Cancer is the leading cause of death globally, with a low early diagnosis rate in China. The government has implemented policies to enhance cancer prevention and treatment, such as the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)" [9]. Group 5: Competitive Landscape - The cancer immunotherapy market is characterized by concentrated leadership and technological differentiation, with key players including Legend Biotech, Akeso, I-Mab, Junshi Biosciences, and others. Notable advancements have been made in CAR-T, bispecific antibodies, and NK therapies [10][11]. Group 6: Future Development Directions - While cancer immunotherapy has transitioned from laboratory concepts to clinical practice, challenges such as resistance, toxicity, and accessibility remain. Future advancements may lead to a shift from "prolonging survival" to "functional cure" through interdisciplinary innovation and policy support [12][13].

该交易对德国政府而言也意味着一种退出方式。在疫情期间，德国政府购入了 CureVac 公司的股份，目 前持有其 13.3%的股权。根据交易条款，德国政府将获得约 1.63 亿美元的 BioNTech 股票。据 BioNTech 称，德国政府对此次交易持积极态度。 智通财经APP获悉，BioNTech(BNTX.US)同意以约 12.5 亿美元的价格全股票收购前新冠疫苗竞争对手 CureVac(CVAC.US)，这将助力其不断发展的肿瘤学业务。该公司周四表示，CureVac 的投资者每持有 1 股 CureVac 股票，就能获得约 5.46 股 BioNTech 股票。这一价格较 CureVac 周三的收盘价高出 34%。交 易完成后，CureVac 的股东将持有 BioNTech 不少于 4%至 6%的股份。消息公布后，截至发稿，CureVac 股价盘前上涨31.20%。 该协议终结了这两家公司长达数十年的竞争关系，这种竞争在研发新冠疫苗的过程中达到了顶点。在新 冠疫苗的竞赛中，BioNTech通过与辉瑞(PFE.US)合作成功赢得了这场比赛，率先完成研发，从而转型 成为欧洲领先的生物技术公司之一。而Cure ...

Group 1 - The core finding of the research is the identification of unique genetic characteristics of T cell clones that may predict the efficacy of cancer immunotherapy, paving the way for personalized treatment approaches [1][2] - Immunotherapy is recognized as a revolutionary breakthrough in cancer treatment, capable of precisely eliminating cancer cells by activating the immune system, but individual patient differences pose significant challenges to its widespread application [1] - The research involved a meta-analysis of single-cell RNA sequencing and T cell receptor sequencing data from numerous cancer patients who underwent immunotherapy, focusing on the relationship between T cell clone characteristics and the success of the therapy [1] Group 2 - The study revealed that while T cell clones exist in both responsive and non-responsive cancer patients, those in responsive patients exhibit a distinct genetic feature and enhanced immune activity due to immunotherapy [2] - It was determined that activating T cell clones present only within tumors, rather than those found in both tumors and blood, is crucial for improving the effectiveness of immunotherapy in treating cancer [2] - This research provides significant insights into the dynamic mechanisms of the human immune system in the cancer fighting process, as published in the latest issue of the journal "Cell Genomics" [2]